Fürst Medical Laboratory scoops up PatoGen

Fish health company PatoGen has been acquired by Norway’s Fürst Medical Laboratory, which has promised to continue developing the business.

PatoGen is a leading provider of preventive and diagnostic analysis for the aquaculture industry in Norway and Scotland. It has operations in Norway – in Ålesund, Oslo and Bodø – and Oban in Scotland. In total, PatoGen has nearly 60 employees and its revenue in 2020 was just under NOK 100m (£8m).

Fürst, which is the largest medical laboratory in Norway, has acquired 100% of PatoGen’s shares. The deal brings it into the aquaculture market for the first time  – its core business is providing analytical services to the healthcare sector.

The CEO of Fürst, Håvard Selby Ebbestad, said: “Fürst has a long lasting and solid experience running effective laboratories and diagnostics. Becoming owners of PatoGen, we also get exposure to preventive and diagnostic analyses in fish. This is an attractive market for us, and we are confident we can make a valuable contribution to the aquaculture companies to improve their fish health and fish welfare.”